Two major products of Yuanda Pharmaceutical have achieved milestone progress

On April 19, 2021, Broad Pharmaceuticals announced that, as a research and development platform in the field of tumor immunotherapy and DNA technology of Broad Pharmaceuticals, OncoSec Medical Incorporated (OncoSec, an associate company of Broad Pharmaceuticals) developed by the US Nasdaq-listed company GenPulse™, a new generation of gene electroporation equipment, recently obtained the European Union CE certification.

At the same time, Grand Pharmaceuticals announced that its wholly-owned subsidiary Grand Medical Pty Ltd (the company’s innovative drug research and development center in Australia) is developing a global innovative drug STC3141 for the field of severe infections.

The new generation of gene transfer equipment GenPulse™

OncoSec is a high-tech innovative biotechnology company that has entered the clinical stage.

The GenPulse™, which has obtained the EU CE certification this time, is part of the OMS electroporation device platform and is used for the treatment of solid tumors.

GenPulse™'s CE certification is an important milestone for OncoSec’s commercialization in Europe.

Innovative drug STC3141

There are few therapeutic drugs with definite curative effect for sepsis.

According to Broad Pharmaceuticals, this time STC3141 was approved to carry out a phase IIa clinical study of new coronary pneumonia in Belgium.

As the headquarters of the European Union, Belgium is an important research and development place for the global treatment of disease drugs and the world's second largest exporter of drugs.